Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (August 2023)
17 slides from Arovella Therapeutics's investor presentation, Aug 15, 2023
Slide 1: Investor Webinar Presentation
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 15 August 2023 INVESTOR WEBINAR PRESENTATION MELBOURNE, AUSTRALIA 15 August 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is ple
Slide 2: Glossary and forward-looking statements
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Glossary: iNKT cell – invariant Natural Killer T cells; CAR – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; TCR – T cell receptors are a group of proteins found on immune cells that recognise fragment
Slide 3: Dr. Michael Baker, August 2023
For personal use only ASX: ALA Dr. Michael Baker August 2023
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In prepa
Slide 5: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights For personal use only Off-the-Shelf iNKT Cell Platform Lead Product Advancing to Clinic Addressing Key Unmet Need Arovella is developing off-the-shelf iNKT cell ALA-101, a potential treatment for CD19-expressing Arovella’s iNKT cell platform is well therapies to targ
Slide 6: Arovella Financial Overview
Arovella Financial Overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 For personal use only Market capitalisation1 $44.5 million 40,000,000 $0.10 Shares on issue 899.1 million 52-week low / high1 $0.020 / $0.105 $0.08 30,000,000 Pro Forma Cash (June 30 2023 + SPP)2 $7.38 mill
Slide 7: What are CAR-T Cells?
What are “CAR-T Cells”? ▪ T cells are a common type of immune cell that fight infections and can help fight cancer For personal use only ▪ To generate autologous CAR-T cells, T cells are taken from a patient with blood cancer and ‘reprogrammed’ to produce a Chimeric Antigen Receptor (CAR) o The CAR
Slide 8: Cell Therapy Has Revolutionized Blood Cancer Treatment
Cell Therapy Has Revolutionized Blood Cancer Treatment ▪ CAR-T cells have demonstrated ability to cure haematological cancers and have generated strong sales ▪ The Cell Therapy market is expected to reach $61.2 billion by 20301 For personal use only February 2022 May 2022 Product Approval 2022 Year
Slide 9: But…Manufacturing and Logistics Pose Major Challenges
But…Manufacturing and Logistics Pose Major Challenges ▪ T cells must originate from the patient to be treated so each manufacturing batch is patient-specific For personal use only Arovella’s CAR-iNKT cell platform has ▪ High manufacturing and supply chain costs lead to high drug the potential to add
Slide 10: Introducing invariant Natural Killer T (iNKT) Cells
Introducing invariant Natural Killer T (iNKT) Cells For personal use only 8
Slide 11: Advantages of iNKT Cells
Advantages of iNKT Cells Front-line of the human immune system ▪ Bridge innate and adaptive immune responses For personal use only ▪ Contain both T cell and NK cell killing mechanisms ▪ Naturally target and kill cancers that express CD1d Strong safety profile ▪ They do not cause graft versus host di
Slide 12: The Potential of CAR-iNKT Cells is Untapped
The Potential of CAR-iNKT Cells is Untapped For personal use only 10 Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information
Slide 13: CAR-iNKT Cell Therapy Production Advantages
CAR-iNKT Cell Therapy Production Advantages Manufacturing Collect Healthy Isolate iNKT cells Reprogram iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells For personal use only Treatment Thaw CAR-iNKT cells Allogeneic Manufacturing Advanta
Slide 14: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets CD19-CAR CD19-CAR DKK1-CAR For personal use only ALA-101 ALA-101 + onCARlytics ALA-104 Cytokine Technology Non- Head and Prostate Brain Triple negative Pancreatic Multiple Hodgkin’s Lung Cancer Neck Cancer Cancer Metastases breast cancer Cancer Myeloma Lymphoma ▪
Slide 15: Milestones FY2024
Milestones FY2024 ▪ Arovella expects to advance ALA-101 into a phase I first-in-human clinical trial in 2024 o Non-Hodgkin’s lymphoma patients, dose escalation, primary end point – DLTs, secondary endpoint – efficacy signals ▪ Arovella also continues to assess novel complimentary technologies to exp
Slide 16: Recent Cell Therapy Transactions
Recent Cell Therapy Transactions Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Stage Upfront ($M) ($M) value ($M) Strategic Investment Aug-23 Phase 1 $25 $0 $25 (ROFR) For personal use only May-23 License Phase Ib $245 undisclosed Jan-23 Acquisition Phase I $200 $120 $320
Slide 17: Thank You
Thank You For personal use only Dr. Michael Baker CEO & Managing Director Email: mbaker@arovella.com Mobile: +61 403 468 187
Arovella Therapeutics — Investor Presentation (August 2023) on 6ix